Helicobacter pylori is a spiral-shaped gram-negative bacterium involved in the development of gastritis, duodenal and gastric ulcers, and gastric cancer.
Infection is strongly associated with the development of gastric epithelial and lymphoid malignancies.
Acute infection is mostly asymptomatic and is acquired through human-to-human contact via gastro-oral and fecal-oral routes.
Adaptability in gastric conditions and production of urease allow it to colonize the stomach.
A 14-day course of reverse hybrid therapy is as effective as bismuth quadruple therapy in the first-line treatment of Helicobacter pylori infection, although the former is associated with fewer adverse events, according to the results of a trial.
Genotypic resistance-guided therapy is no better than traditional empiric therapy for treating patients with refractory Helibacter pylori infection. Researchers found no significant difference in eradication rate between the two strategies when used in the third-line setting.
The increasing resistance to certain antibiotics in Helicobacter pylori (H. pylori) eradication therapies is associated with a reduction in treatment efficacy in Asia-Pacific countries, and treatments should be adapted accordingly, according to a systematic review and meta-analysis.
High consumption of fish and egg appears to be negatively associated with successful Helicobacter pylori eradication therapy in H. pylori‒positive patients with gastritis and/or duodenal ulcers, a recent study has found.
The vonoprazan-based triple therapy is superior to proton pump inhibitor-based triple therapy in terms of Helicobacter pylori eradication, although the two regimens show comparable tolerability and incidence of adverse events, according to a review and meta-analysis.
Helicobacter pylori (H. pylori) infection is associated with conditions such as gastritis, peptic ulcer, gastric cancer, and certain types of lymphoma. A common presenting complaint among all these H. pylori-related illnesses is dyspepsia. Dr Desmond Wai from the Desmond Wai Liver and Gastrointestinal Diseases Centre, Mount Elizabeth Novena Specialist Centre, Singapore, speaks on the important role general practitioners (GPs) play in recognizing, diagnosing, and treating H. pylori.
The novel bismuth-containing quadruple therapy with metronidazole and amoxicillin appears to be an attractive alternative to classical therapy with tetracycline for Helicobacter pylori rescue treatment, according to a study. The former demonstrates comparable eradication rates with superior safety and compliance.
A new study reinforces the gut-brain connection in Alzheimer’s disease (AD), untangling the complex interplay between gut and brain health that could potentially lead to new therapies targeted at manipulating the gut microbiome to treat AD.
Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.